MedPath

Inodiftagene vixteplasmid

Generic Name
Inodiftagene vixteplasmid
Drug Type
Biotech
CAS Number
2166100-08-7
Unique Ingredient Identifier
98YK326XZ6
Background

Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed non-protein coding gene).

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Phase 2
Terminated
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
First Posted Date
2018-10-25
Last Posted Date
2020-08-19
Lead Sponsor
Anchiano Therapeutics Israel Ltd.
Target Recruit Count
32
Registration Number
NCT03719300
Locations
๐Ÿ‡บ๐Ÿ‡ธ

American Institute of Research, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

The University of Kansas Cancer Center, Westwood, Kansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Idaho Urologic Institute, PA, Meridian, Idaho, United States

and more 45 locations

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Phase 1
Completed
Conditions
Transitional Cell Carcinoma of Bladder
Interventions
First Posted Date
2013-06-14
Last Posted Date
2019-03-11
Lead Sponsor
Anchiano Therapeutics Israel Ltd.
Target Recruit Count
38
Registration Number
NCT01878188
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Tel Aviv Medical Center, Tel Aviv, Israel

๐Ÿ‡ฎ๐Ÿ‡ฑ

Carmel Medical Center, Haifa, Israel

๐Ÿ‡ฎ๐Ÿ‡ฑ

Bnai Zion MC, Haifa, Israel

and more 4 locations

Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer

Phase 1
Completed
Conditions
Bladder Neoplasms
First Posted Date
2006-10-29
Last Posted Date
2008-01-07
Lead Sponsor
Hebrew University of Jerusalem
Target Recruit Count
18
Registration Number
NCT00393809
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Meir Medical Center, Kfar Saba, Israel

๐Ÿ‡ฎ๐Ÿ‡ฑ

E. Wolfson Medical Center, Holon, Israel

ยฉ Copyright 2025. All Rights Reserved by MedPath